Back to top
more

Harpoon Therapy Inc. (HARP)

(Delayed Data from NSDQ)

$10.59 USD

10.59
19,408

-0.41 (-3.73%)

Updated May 3, 2019 04:13 PM ET

After-Market: $10.33 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

[HARP]

Reports for Purchase

Showing records 1 - 20 ( 162 total )

Industry: Medical - Drugs

Record: 1

03/12/2024

Company Report

Pages: 6

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

01/08/2024

Company Report

Pages: 6

Merck to Acquire Harpoon Therapeutics; Downgrade to Neutral With $23 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

12/13/2023

Company Report

Pages: 10

Phase 1 Data Update Reinforces HPN217?s Potential in r/r MM; New $12 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for HARP 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

11/10/2023

Company Report

Pages: 9

Promising Potential of HPN328 in SCLC and Beyond; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

09/29/2023

Daily Note

Pages: 5

Clinical Data Update Continues to Show Strong HPN217 Potential; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

09/14/2023

Company Report

Pages: 6

HPN217 Becomes Unencumbered; New $7.50 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

08/10/2023

Company Report

Pages: 6

Data-Rich 2H23; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

05/15/2023

Company Report

Pages: 6

Selection of RP2Ds for HPN217 and HPN328 in 2H23; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

03/29/2023

Company Report

Pages: 8

Catalyst-Rich 2H23; Dilution-Led Lower PT To $4.50; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

01/06/2023

Company Report

Pages: 4

Dropping Coverage

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

01/03/2023

Industry Report

Pages: 65

Multiple Myeloma Landscape - CD38, BCMA, GPRC5D, and FcRH5 (Version 1.0)

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

11/16/2022

Company Report

Pages: 7

Spotlight on HPN217 Results at ASH; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

08/15/2022

Company Report

Pages: 9

Steady Pipeline Progress; Awaiting Development Partnership For HPN536; Lower PT to $7; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

08/15/2022

Company Report

Pages: 6

Q2 Financials; HPN217 Data Ahead in Q4:22

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

06/09/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

05/31/2022

Industry Report

Pages: 11

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

05/31/2022

Daily Note

Pages: 4

Weekly ReHash: Deferred Taxes, Another Low "Cost" Cash Opportunity

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

05/29/2022

Industry Report

Pages: 17

2022 Abstract Roundup For Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

05/27/2022

Company Report

Pages: 6

HPN328''s ASCO Data Should Be Encouraging, but Only an Incremental Update

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party
// eof